Ubs Group Ag Dexcom Inc Put Options Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

Put Options

14 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$64.0 - $116.06 $17 Million - $30.9 Million	266,100 Added 93.3%	551,300 $36.9 Million
Q2 2024 Aug 13, 2024	BUY	$110.31 - $140.45 $5.59 Million - $7.12 Million	50,700 Added 21.62%	285,200 $32.3 Million
Q1 2024 May 13, 2024	BUY	$114.22 - $140.1 $7.54 Million - $9.25 Million	66,000 Added 39.17%	234,500 $32.5 Million
Q4 2023 Feb 09, 2024	SELL	$75.49 - $124.16 $2.15 Million - $3.54 Million	-28,500 Reduced 14.47%	168,500 $20.9 Million
Q3 2023 Nov 09, 2023	BUY	$86.06 - $137.93 $6.02 Million - $9.64 Million	69,900 Added 55.0%	197,000 $18.4 Million
Q2 2023 Aug 11, 2023	BUY	$112.47 - $130.98 $7.29 Million - $8.49 Million	64,800 Added 104.01%	127,100 $16.3 Million
Q1 2023 May 12, 2023	BUY	$104.0 - $122.92 $6.35 Million - $7.51 Million	61,078 Added 4998.2%	62,300 $7.24 Million
Q4 2022 Feb 08, 2023	SELL	$84.98 - $122.67 $4.15 Million - $5.98 Million	-48,778 Reduced 97.56%	1,222 $138,000
Q3 2022 Nov 10, 2022	BUY	$76.35 - $94.18 $3.82 Million - $4.71 Million	50,000 New	50,000 $4.03 Million
Q2 2021 Aug 13, 2021	SELL	$80.99 - $107.93 $809,900 - $1.08 Million	-10,000 Reduced 66.67%	5,000 $2.14 Million
Q1 2021 May 12, 2021	BUY	$84.79 - $104.74 $508,740 - $628,440	6,000 Added 66.67%	15,000 $5.39 Million
Q2 2020 Jul 31, 2020	BUY	$62.68 - $105.34 $238,184 - $400,292	3,800 Added 73.08%	9,000 $3.65 Million
Q3 2019 Nov 14, 2019	SELL	$35.53 - $43.8 $113,696 - $140,160	-3,200 Reduced 38.1%	5,200 $776,000
Q1 2019 May 14, 2019	BUY	$28.07 - $38.18 $235,788 - $320,712	8,400 New	8,400 $1 Million

Others Institutions Holding DXCM

# of Institutions

1,013

Shares Held

351M

Call Options Held

5.51M

Put Options Held

5.6M

View Full List

About DEXCOM INC

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $29.5B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

More about DXCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account